Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02107872 | Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500 | PHASE1 | COMPLETED | 55 | — | — | Apr 1, 2014 | Sep 1, 2015 | Sep 30, 2015 | 4 | United States |
Safety of REGN1500 will be assessed by physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations from visit 1 to day 183 \[EOS (end of study)\]
| Arm | Type | Description |
|---|---|---|
| dosing cohort 1 | EXPERIMENTAL | Patients will receive REGN1500 or placebo in dosing cohort 1 |
| dosing cohort 2 | EXPERIMENTAL | Patients will receive REGN1500 or placebo in dosing cohort 2 |
| dosing cohort 3 | EXPERIMENTAL | Patients will receive REGN1500 or placebo in dosing cohort 3 |
| dosing cohort 4 | EXPERIMENTAL | Patients will receive REGN1500 or placebo in dosing cohort 4 |
| dosing cohort 5 | EXPERIMENTAL | Patients will receive REGN1500 or placebo in dosing cohort 5 |
| Name | Type | Description |
|---|---|---|
| REGN1500 | DRUG | - |
| placebo | DRUG | - |
Inclusion Criteria: * Provide signed informed consent * Otherwise healthy men and women ages 18 to 65 years, inclusive * Body mass index of 18.0 kg/m2to 38.0 kg/m2, inclusive * Normal standard 12-lead ECG * Willing to refrain from the consumption of alcohol for 24 hours prior to each study visit * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | mibavademab, Mibavademab |
| MBX Biosciences, Inc. | MBX | 1 | PHASE2 | MBX 1416 |
| DexCom, Inc. | DXCM | 1 | — | Undisclosed |